U.S. Markets open in 31 mins
  • S&P Futures

    4,240.75
    +30.75 (+0.73%)
     
  • Dow Futures

    33,519.00
    +259.00 (+0.78%)
     
  • Nasdaq Futures

    13,494.25
    +102.25 (+0.76%)
     
  • Russell 2000 Futures

    1,985.20
    +15.70 (+0.80%)
     
  • Crude Oil

    93.41
    +1.48 (+1.61%)
     
  • Gold

    1,812.00
    -1.70 (-0.09%)
     
  • Silver

    20.56
    -0.19 (-0.90%)
     
  • EUR/USD

    1.0351
    +0.0049 (+0.4761%)
     
  • 10-Yr Bond

    2.7500
    -0.0360 (-1.29%)
     
  • Vix

    19.83
    -1.94 (-8.91%)
     
  • GBP/USD

    1.2235
    +0.0016 (+0.1346%)
     
  • USD/JPY

    131.9430
    -0.9300 (-0.6999%)
     
  • BTC-USD

    24,742.35
    +876.69 (+3.67%)
     
  • CMC Crypto 200

    584.58
    +53.36 (+10.05%)
     
  • FTSE 100

    7,468.63
    -38.48 (-0.51%)
     
  • Nikkei 225

    27,819.33
    -180.67 (-0.65%)
     

Athersys to Participate in the H.C. Wainwright Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CLEVELAND, May 13, 2022--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida. The Company’s management team will also participate in one-on-one meetings with institutional investors during the conference.

Investors interested in arranging a meeting with the Company’s management during the conference should contact meetings@hcwo.com or dwilliamson@hcwo.com. The Company’s presentation will be available on-demand beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. This event can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website. An archived replay of the webcast will be available on the Company's website after the conference for a limited time.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005045/en/

Contacts

Ivor Macleod
Chief Financial Officer
Tel: (216) 431-9900
ir@athersys.com

Karen Hunady
Director of Corporate Communications & Investor Relations
Tel: (216) 431-9900
khunady@athersys.com

David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
David.schull@russopartnersllc.com

Peter Vozzo
ICR Westwicke
Tel: (443) 213-0505
peter.vozzo@westwicke.com